Antimicrobial properties and bioactivity of zirconia-based biocomposites
Artificial Cells, Nanomedicine, and Biotechnology · Published 2025-08-02 · DOI 10.1080/21691401.2025.2540647
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1080/21691401.2025.2540647
Abstract
Zirconia-based composites are promising materials for medical and dental applications. They are widely used due to their osteoconductivity and chemical stability. Moreover, when modified with beneficial fillers, they combine mechanical strength with bioactivity. This study addresses the interplay between bioactive fillers, cytotoxicity, antibacterial activity, and reactive oxygen species (ROS) levels in ZrO2 composites. The composites were tested for their biological properties. Thanks to hydrothermally obtained zirconia used in ZrO2/HAp composites the sintering temperature was reduced, which limited hydroxyapatite decomposition. However, ZrO2/HAp composites revealed higher cytotoxicity and ROS levels, linked to calcium ion release resulting from the partial HAp decomposition. Composites with BGCu exhibited strong antibacterial activity and acceptable cytotoxicity due to copper ions disrupting microbial structures and inducing oxidative stress. hBN-containing composites displayed moderate bacteriostatic activity but higher cytotoxicity than BGCu composites. These findings highlight the potential of ZrO2/BGCu composites as bioactive materials for bone regeneration and antimicrobial applications. While composites with hydroxyapatite demonstrate a balance between bioactivity and cytotoxicity, BGCu emerge as a promising modification to enhance antibacterial properties with controlled cytotoxicity. Further research is needed to optimise filler compositions to balance ion release, biological stability, and functionality.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2025
Related articles
- Molecular mechanisms of phytochemicals from Zanthoxylum nitidum (Roxb.) DC. against hepatocellular carcinoma: insights from network pharmacology, molecular docking, and bioinformatics · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Human tendon stem/progenitor cell-derived extracellular vesicle production promoted by dynamic culture · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Characterization of genipin-crosslinked gelatin/PVA hydrogels and the chondroprotective influence of hydroxytyrosol: an In vitro study · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Identification of mitophagy-related biomarkers in human rheumatoid arthritis using machine learning models · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Multi-omics analysis of the potential association between ageing and rheumatoid arthritis and screening of potential therapeutic targets · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Cross-talk between diabetic nephropathy and bone loss: PBMCs-guided discovery of NLRP3-inflammatory signalling · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Exosome-mediated perturbation of the immune-bone metabolism axis: a mechanistic investigation into bone loss in a simulated microgravity environment · Artificial Cells, Nanomedicine, and Biotechnology · 2025 · Same journal
- Bio-Inspired lipid nanovesicles (iNVs) incorporating membrane proteins from healthy tendon stem cells for targeted protein restoration in tendinopathic in vitro model · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Novel anti-rheumatic potential of Eucalrobusone C: inhibition of rheumatoid arthritis fibroblast-like synoviocytes and metabolic reprogramming · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal
- Engineering nanobodies for drug delivery systems in Alzheimer’s disease · Artificial Cells, Nanomedicine, and Biotechnology · 2026 · Same journal